Christopher Counter

Company: Duke University

Job title: Professor

Seminars:

Interrogating the RAS Interactome for New Therapeutic Opportunities 3:30 pm

Combining proximity labelling with CRISPR/Cas9 loss-of-function screening identified the interactomes of each RAS isoform Mining these datasets for isoform-specific interactions identified PIP5K1A as specifically binding to and promoting oncogenic KRAS, but not NRAS or HRAS signalling and transformation, providing a new therapeutic opportunity Mining these datasets for the top dependency identified EFR3A as a new…Read more

day: Day Two Track D